...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America. >Estrogen receptor beta, a regulator of androgen receptor signaling in the mouse ventral prostate
【24h】

Estrogen receptor beta, a regulator of androgen receptor signaling in the mouse ventral prostate

机译：Estrogen receptor beta, a regulator of androgen receptor signaling in the mouse ventral prostate

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

As estrogen receptor beta(-/-) (ER beta(-/-)) mice age, the ventral prostate (VP) develops increased numbers of hyperplastic, fibroplastic lesions and inflammatory cells. To identify genes involved in these changes, we used RNA sequencing and immunohistochemistry to compare gene expression profiles in the VP of young (2-mo-old) and aging (18-mo-old) ER beta(-/-) mice and their WT littermates. We also treated young and old WT mice with an ER beta-selective agonist and evaluated protein expression. The most significant findings were that ER beta down-regulates androgen receptor (AR) signaling and up-regulates the tumor suppressor phosphatase and tensin homolog (PTEN). ER beta agonist increased expression of the AR corepressor dachshund family (DACH1/ 2), T-cadherin, stromal caveolin-1, and nuclear PTEN and decreased expression of RAR-related orphan receptor c, Bcl2, inducible nitric oxide synthase, and IL-6. In the ER beta-/mouse VP, RNA sequencing revealed that the following genes were up-regulated more than fivefold: Bcl2, clusterin, the cytokines CXCL16 and -17, and a marker of basal/ intermediate cells (prostate stem cell antigen) and cytokeratins 4, 5, and 17. The most downregulated genes were the following: the antioxidant gene glutathione peroxidase 3; protease inhibitors WAP four-disulfide core domain 3 (WFDC3); the tumor-suppressive genes T-cadherin and caveolin-1; the regulator of transforming growth factor beta signaling SMAD7; and the PTEN ubiquitin ligase NEDD4. The role of ER beta in opposing AR signaling, proliferation, and inflammation suggests that ER beta-selective agonists may be used to prevent progression of prostate cancer, prevent fibrosis and development of benign prostatic hyperplasia, and treat prostatitis.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号